Northwest Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NWBO research report →
Price Chart
About the company
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform.
- CEO
- Linda F. Powers
- IPO
- 2001
- Employees
- 105
- HQ
- Bethesda, MD, US
Get TickerSpark's AI analysis on NWBO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $246.50M
- P/E
- -6.05
- PEG
- -0.06
- P/S
- 113.44
- P/B
- -7.08
- EV/EBITDA
- -5.25
- Div Yield
- 0.00%
- Gross Margin
- -39.02%
- Op Margin
- -2316.11%
- Net Margin
- -1736.36%
- ROE
- 69.98%
- ROIC
- -136.62%
Latest fiscal year · YoY change
- Revenue
- $1.38M-0.3%
- Gross Profit
- $-959,000-169.4%
- Op Income
- $-59,914,000
- Net Income
- $-61,477,000+26.6%
- EPS
- $-0.04+38.5%
- OCF Growth
- +21.5%
- FCF Growth
- +20.3%
- 52W High
- $0.34
- 52W Low
- $0.14
- 50D MA
- $0.17
- 200D MA
- $0.21
- Beta
- -0.61
- RSI (14)
- 40
- Avg Volume
- 3.28M
No earnings-call transcripts are available for NWBO yet.
- Free Float
- 97.8%
- Shares Outstanding
- 1.64B
- Float Shares
- 1.61B
of shares held by institutions
6 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Compass Financial Management LLC | 1.22M | ▲ 1.22M |
| Kelleher Financial Advisors | 800.00K | ▲ 600.00K |
| Moloney Securities Asset Management, LLC | 534.71K | ▲ 33.15K |
| Vsm Wealth Advisory, LLC | 80.57K | 0 |
| Opus Capital Group, LLC | 60.15K | 0 |
| Ethos Financial Group, LLC | 39.07K | 0 |
| Williams Jones Wealth Management, LLC. | 25.00K | 0 |
| Mcilrath & Eck, LLC | 600 | ▲ 600 |
| Strive Financial Group ,LLC | 100 | ▲ 100 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 29, 24 | BOYNTON ALTON L | other | 1,000,000 |
| Aug 9, 24 | BOSCH MARNIX L | other | 3,000,000 |
| Aug 8, 24 | BOYNTON ALTON L | other | 1,000,000 |
| Jul 26, 24 | MALIK NAVID | sell | 657,895 |
| Nov 16, 23 | MALIK NAVID | sell | 125,000 |
| Nov 17, 23 | MALIK NAVID | sell | 150,000 |
| Nov 17, 23 | MALIK NAVID | sell | 295,000 |
| Apr 3, 23 | BOSCH MARNIX L | other | 119,355 |
| Apr 4, 23 | BOYNTON ALTON L | other | 6,794,191 |
| May 26, 22 | BOYNTON ALTON L | other | 4,900,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NWBO coverage
Recent articles, reports, and earnings notes.
No research on NWBO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NWBO report →Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production
prnewswire.com · Oct 8
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production
prnewswire.com · Oct 8
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference
prnewswire.com · Oct 6
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
gurufocus.com · Aug 6
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
prnewswire.com · Aug 6
Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
prnewswire.com · Jul 8
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
prnewswire.com · Jul 2
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
prnewswire.com · Jul 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.